Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.
Zoledronic acid was granted FDA approval on 20 August 2001.
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants
- Conditions
- Interventions
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 59
- Registration Number
- NCT00580047
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT00577642
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
- Conditions
- Interventions
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT00566618
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
- Conditions
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 139
- Registration Number
- NCT00558272
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
- Conditions
- Interventions
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 3420
- Registration Number
- NCT00556374
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy
- Conditions
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- University Hospital Birmingham
- Target Recruit Count
- 300
- Registration Number
- NCT00554918
- Locations
- 🇬🇧
Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom
🇬🇧Gloucestershire Oncology Centre at Cheltenham General Hospital, Cheltenham, England, United Kingdom
🇬🇧Christie Hospital, Manchester, England, United Kingdom
Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 60
- Registration Number
- NCT00524849
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer
- First Posted Date
- 2007-08-23
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Wirral University Teaching Hospital NHS Trust
- Target Recruit Count
- 58
- Registration Number
- NCT00520052
- Locations
- 🇬🇧
Wirral Hospitals Universirt NHS Trust, Upton, Wirral, Merseyside, United Kingdom
Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 654
- Registration Number
- NCT00512993
- Locations
- 🇦🇹
LKH-Univ. Klinikum Graz, Onkologie, Graz, Styria, Austria
🇦🇹LKH Salzburg, Uni.klinik f. Innere Med. III/Onkol. Amb., Salzburg, Austria
🇩🇪Frauenklinik Rheinfelden, Rheinfelden, Baden-Württemberg, Germany
Zoledronate With Atorvastatin in Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2013-03-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT00490698
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.